Immuneering Beheer
Beheer criteriumcontroles 4/4
De CEO Immuneering is Ben Zeskind, benoemd in Feb2008, heeft een ambtstermijn van 18.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.66M, bestaande uit 38.6% salaris en 61.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 4.96% van de aandelen van het bedrijf, ter waarde $ 16.90M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.4 jaar en 5 jaar.
Belangrijke informatie
Ben Zeskind
Algemeen directeur
US$1.7m
Totale compensatie
| Percentage CEO-salaris | 38.63% |
| Dienstverband CEO | 18.5yrs |
| Eigendom CEO | 5.0% |
| Management gemiddelde ambtstermijn | 4.4yrs |
| Gemiddelde ambtstermijn bestuur | 5yrs |
Recente managementupdates
Recent updates
Seeking Alpha • Jul 27
Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Summary Immuneering Corporation targets first-line pancreatic cancer with atebimetinib, showing promising Phase 2a results versus standard-of-care regimens. IMRX's pivotal Phase 3 trial in first-line PDAC is recruiting, with first patient dosing expected mid-2026 and cash runway projected into 2029. Atebimetinib demonstrated median overall survival of 17.3 months, outperforming historical controls and comparing favorably to competitors’ data. Despite strong clinical data and differentiated tolerability, IMRX trades at a deep discount to peers, presenting a high-risk, high-reward opportunity. Read the full article on Seeking AlphaAnalyse-artikel • Jun 30
Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Nieuw narratief • Mar 19
Pancreatic Cancer Breakthrough And Long Patent Tail Will Transform This Oncology Platform
Catalysts About Immuneering Immuneering is a biotechnology company focused on developing atebimetinib, a MEK inhibitor, for cancers driven by the MAP kinase pathway, with an initial focus on first line pancreatic cancer and expansion into lung cancer and other tumor types. What are the underlying business or industry changes driving this perspective?
Nieuw narratief • Mar 05
Pivotal Pancreatic Cancer Trial And Extended Patent Protection Will Shape A Long Runway
Catalysts About Immuneering Immuneering is a clinical stage biotech company focused on developing atebimetinib, a MEK inhibitor, for cancers driven by the MAP kinase pathway, with an initial focus on first line pancreatic cancer and expansion into lung cancer. What are the underlying business or industry changes driving this perspective?Analyse-artikel • Nov 22
Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Immuneering...Analyse-artikel • Jul 01
Here's Why Immuneering (NASDAQ:IMRX) Must Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyse-artikel • Mar 18
Immuneering (NASDAQ:IMRX) Will Have To Spend Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Analyse-artikel • Aug 30
Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Analyse-artikel • May 13
Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Mar 19
Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone
Summary Positive safety and anti-tumor activity released from phase 1 portion of phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Additional expansion cohort results from the phase 2 portion of the phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors, expected later in 2024. IMM-6-415 is another MAPK pathway targeting drug, but is able to target either RAS or RAF solid tumors; Dosing of first patient in phase 1 study expected in March 2024. Immuneering had $85.7 million in cash as of December 31st of 2023; Enough cash to fund its operations into the 2nd half of 2025. Read the full article on Seeking AlphaAnalyse-artikel • Jan 06
Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analyse-artikel • Aug 17
We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Sep 30
Immuneering wins FDA nod to study lead asset in solid tumors
The development-stage biotech Immuneering Corporation (NASDAQ:IMRX) announced Friday that the FDA greenlighted its Investigational New Drug (IND) application to study IMM-1-104, its lead candidate targeted at advanced RAS mutant solid tumors. Accordingly, the company expects to begin a Phase 1/2a clinical trial to assess the oral, once-daily therapy in advanced RAS mutant solid tumors across five clinical sites in the U.S. IMRX expects to follow the Phase 1 segment of the study with a dose expansion Phase 2a portion targeted at RAS mutated pancreatic, melanoma, colorectal, and lung cancers. The first patient is expected to enroll in Q4 2022. “Clearance of the IND for IMM-1-104 brings us one step closer to our goal of developing medicines with the potential to benefit every cancer patient with a RAS mutant solid tumor, not just those harboring specific mutations,” Chief Executive Ben Zeskind said. The announcement of the IND submission for IMM-1-104 sent IMRX shares higher early this month.Seeking Alpha • Sep 02
Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate
The shares of development-stage biotech Immuneering Corporation (NASDAQ:IMRX) added ~9% in the pre-market trading Friday after the company announced the filing of an Investigational New Drug (IND) seeking FDA clearance to conduct a clinical trial for its lead asset IMM-1-104. An oral once-daily small molecule, IMM-1-104, targets advanced solid tumors with RAS mutations, unlike the candidates that target specific cancer mutations such as KRAS-G12C. “The preclinical data package for IMM-1-104 is uniquely compelling, and we are excited to now evaluate this compound in patients who so urgently need new options,” the Chief Executive of IMRX, Brett Hall, noted. With the IND submission, the FDA will review the company’s application to determine if the data support the safety of IMM-1-104. IMRX plans to conduct a Phase 1/2a clinical trial of IMM-1-104 across five internationally recognized clinical sites in the U.S. Amgen (AMGN) and Mirati Therapeutics (MRTX) are among the developers of cancer therapies targeted at KRAS G12C mutations.Seeking Alpha • Jul 08
Immuneering initiated a Buy by Chardan, PT set to $18
Immuneering (NASDAQ:IMRX) initiated with a Buy by Chardan analyst Geulah Livshits and gave $18 as price target. The analyst likes the potential of Immuneering's pipeline and translational bioinformatics platform to address unmet needs in diverse cancers. The company's approach integrates analysis of high-throughput transcriptional, genomics, and proteomics datasets to generate insights into tumor signaling dynamics, and mechanisms of therapy response or resistance, to advance drug candidates with optimal signaling profiles, Livshits tells investors in a research note. Currently, the stock is trading at $6.3, a rise of ~10.7% on Friday. Stock has slumped about 64% over the last one year and company has a market cap of $139M . The stock is given a Wall Street 'Strong Buy' rating with 4.5 score (4 Strong Buy, 1 Buy, 1 Hold) Comparative rating of the stock against the peers:Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$57m |
| Mar 31 2026 | n/a | n/a | -US$54m |
| Dec 31 2025 | US$2m | US$641k | -US$56m |
| Sep 30 2025 | n/a | n/a | -US$62m |
| Jun 30 2025 | n/a | n/a | -US$62m |
| Mar 31 2025 | n/a | n/a | -US$62m |
| Dec 31 2024 | US$2m | US$617k | -US$61m |
| Sep 30 2024 | n/a | n/a | -US$58m |
| Jun 30 2024 | n/a | n/a | -US$56m |
| Mar 31 2024 | n/a | n/a | -US$54m |
| Dec 31 2023 | US$2m | US$593k | -US$53m |
| Sep 30 2023 | n/a | n/a | -US$52m |
| Jun 30 2023 | n/a | n/a | -US$52m |
| Mar 31 2023 | n/a | n/a | -US$51m |
| Dec 31 2022 | US$2m | US$570k | -US$51m |
| Sep 30 2022 | n/a | n/a | -US$48m |
| Jun 30 2022 | n/a | n/a | -US$44m |
| Mar 31 2022 | n/a | n/a | -US$40m |
| Dec 31 2021 | US$2m | US$400k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$29m |
| Jun 30 2021 | n/a | n/a | -US$24m |
| Mar 31 2021 | n/a | n/a | -US$20m |
| Dec 31 2020 | US$806k | US$293k | -US$17m |
Compensatie versus markt: De totale vergoeding ($USD 1.66M ) Ben } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.41M ).
Compensatie versus inkomsten: De vergoeding van Ben is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Ben Zeskind (43 yo)
18.5yrs
Tenure
US$1,660,612
Compensatie
Dr. Benjamin J. Zeskind, also known as Ben, Ph D., MBA serves as the Co-Founder, President, Chief Executive Officer and Director of Immuneering Corporation since February 2008 and served as its Secretary....
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 18.5yrs | US$1.66m | 4.96% $ 16.9m | |
| Co-Founder & Chair Emeritus | 18.6yrs | US$93.52k | 1.78% $ 6.0m | |
| Chief Scientific Officer | 6.8yrs | US$1.29m | 0.59% $ 2.0m | |
| Chief Legal Officer & Secretary | 5.1yrs | US$890.36k | 0.0075% $ 25.6k | |
| CFO & Treasurer | less than a year | geen gegevens | 0.35% $ 1.2m | |
| Senior Director of Accounting & Operations and Assistant Corporate Controller | 4.9yrs | geen gegevens | geen gegevens | |
| Senior VP of Finance | 4yrs | geen gegevens | 0.043% $ 145.0k | |
| Director of Quality Systems & Compliance | less than a year | geen gegevens | geen gegevens | |
| Vice President of Corporate Communications | less than a year | geen gegevens | geen gegevens | |
| Chief People Officer | 3.8yrs | geen gegevens | 0.046% $ 155.8k | |
| Head of Discovery & VP | no data | geen gegevens | geen gegevens | |
| Head of Translational Pharmacology & VP | 4.4yrs | geen gegevens | geen gegevens |
4.4yrs
Gemiddelde duur
54yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van IMRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.4 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Co-Founder | 18.5yrs | US$1.66m | 4.96% $ 16.9m | |
| Co-Founder & Chair Emeritus | 17.3yrs | US$93.52k | 1.78% $ 6.0m | |
| Independent Director | 5.4yrs | US$106.81k | 0.022% $ 73.7k | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Chairman of the Board | 2.4yrs | US$104.89k | 0.12% $ 392.4k | |
| Director | 5.6yrs | US$103.38k | 1.79% $ 6.1m | |
| Member of Pancreatic Cancer Advisory Board | 1.7yrs | geen gegevens | geen gegevens | |
| Independent Director | 4.6yrs | US$101.52k | 0.0085% $ 29.0k | |
| Member of Pancreatic Cancer Advisory Board | 1.7yrs | geen gegevens | geen gegevens |
5.0yrs
Gemiddelde duur
66yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van IMRX wordt beschouwd als ervaren (gemiddelde ambtstermijn 5 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/08/21 09:18 |
| Aandelenkoers aan het einde van de dag | 2026/08/20 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Immuneering Corporation wordt gevolgd door 11 analisten. 8 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Li Wang Watsek | Cantor Fitzgerald & Co. |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Andres Maldonado | H.C. Wainwright & Co. |